Mukambro (Ambroxol Hydrochloride)

Ambroxol Hydrochloride enhances the production of pulmonary surfactant and breaks down mucopolysaccharide structures in bronchial secretions. This reduces mucus viscosity, promotes ciliary activity, and facilitates the removal of mucus from the airways, thereby easing cough and improving ventilation.

The appropriate dose of Mukambro is determined by the prescribing healthcare professional based on the patient’s age, clinical condition, and response to therapy. Dosage regimens may vary, and the prescriber will provide specific instructions tailored to each individual.

Safety data for Ambroxol Hydrochloride in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Mukambro product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both Ambroxol (Mukambro) and acetylcysteine act as mucolytics, but Ambroxol also stimulates surfactant production, which can improve cough efficiency and reduce irritation. Acetylcysteine primarily breaks disulfide bonds in mucus. Choice of agent depends on clinical judgment, patient tolerance, and specific therapeutic goals.

Mukambro should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture, excessive heat, and direct sunlight. Ensure the container is tightly closed when not in use to maintain stability.

Mukambro is intended for oral administration. The tablet or liquid is taken by mouth with or without food, as directed by the prescriber. Swallow the tablet whole with water, or measure the liquid dose accurately using a calibrated device before ingestion.

Serious adverse reactions, although rare, include severe allergic responses such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, hepatic dysfunction, neutropenia, and bronchospasm. Patients should seek immediate medical attention if they experience symptoms such as rash, difficulty breathing, jaundice, or unexplained fever.

Mukambro should be avoided in individuals with known hypersensitivity to Ambroxol Hydrochloride or any excipients in the formulation. Caution is advised for patients with severe renal or hepatic impairment, and it should be used only under medical supervision in pregnant or breastfeeding women.